Roche Pharmaceutical Images - Search News

Roche, obesity and Zealand

Pharmaceutical Technology on M… · 3d

Zealand and Roche strike $5.3bn obesity treatment deal

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

CNBC on MSN · 3d

Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Investor's Business Daily on MSN · 3d

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

3don MSN

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

3don MSN

Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results